Genentech's Avastin Gaining Market Share In On- And Off-Label Indications

Avastin's share in the first-line metastatic colorectal cancer setting reached 55% in the fourth quarter, up from 42% in the third quarter. Off-label use in the second-line increased to 41%. An August "Dear Doctor" letter on thromboembolic events may have had an impact on slower-than-expected fourth quarter sales of the oncologic.